Raymond James & Associates Has $2.61 Million Stake in CareDx, Inc (NASDAQ:CDNA)

Raymond James & Associates lifted its holdings in shares of CareDx, Inc (NASDAQ:CDNAGet Rating) by 3.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 153,096 shares of the company’s stock after acquiring an additional 4,464 shares during the period. Raymond James & Associates’ holdings in CareDx were worth $2,606,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Rhumbline Advisers grew its position in shares of CareDx by 0.9% during the 1st quarter. Rhumbline Advisers now owns 55,130 shares of the company’s stock worth $2,039,000 after buying an additional 481 shares during the period. Neuberger Berman Group LLC grew its position in shares of CareDx by 1.0% during the 1st quarter. Neuberger Berman Group LLC now owns 59,225 shares of the company’s stock worth $2,191,000 after buying an additional 587 shares during the period. Raymond James Financial Services Advisors Inc. grew its position in shares of CareDx by 1.1% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 56,031 shares of the company’s stock worth $954,000 after buying an additional 630 shares during the period. Lazard Asset Management LLC grew its position in shares of CareDx by 32.0% during the 1st quarter. Lazard Asset Management LLC now owns 3,225 shares of the company’s stock worth $119,000 after buying an additional 782 shares during the period. Finally, Perkins Capital Management Inc. boosted its stake in CareDx by 1.4% during the 2nd quarter. Perkins Capital Management Inc. now owns 58,492 shares of the company’s stock worth $1,256,000 after acquiring an additional 800 shares during the last quarter.

CareDx Stock Performance

Shares of CDNA opened at $14.33 on Friday. CareDx, Inc has a twelve month low of $10.50 and a twelve month high of $46.88. The firm’s 50 day moving average price is $12.59 and its two-hundred day moving average price is $17.45. The firm has a market cap of $767.19 million, a P/E ratio of -10.16 and a beta of 0.92.

CareDx (NASDAQ:CDNAGet Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. CareDx had a negative net margin of 23.36% and a negative return on equity of 16.51%. The firm had revenue of $79.36 million for the quarter, compared to analyst estimates of $81.66 million. On average, sell-side analysts anticipate that CareDx, Inc will post -1.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CDNA shares. The Goldman Sachs Group reduced their price objective on shares of CareDx from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, November 4th. StockNews.com raised shares of CareDx from a “sell” rating to a “hold” rating in a research note on Friday, November 4th. BTIG Research reduced their price objective on shares of CareDx from $37.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 7th. Finally, Raymond James reduced their price objective on shares of CareDx from $35.00 to $26.00 and set a “strong-buy” rating on the stock in a research note on Monday, November 7th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, CareDx presently has a consensus rating of “Buy” and an average target price of $46.20.

Insider Transactions at CareDx

In other news, insider Reginald Seeto sold 2,818 shares of the business’s stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $11.69, for a total value of $32,942.42. Following the sale, the insider now owns 268,906 shares of the company’s stock, valued at $3,143,511.14. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 5.00% of the stock is currently owned by insiders.

CareDx Company Profile

(Get Rating)

CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Featured Articles

Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc (NASDAQ:CDNAGet Rating).

Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.